Synaptic vesicle mimics affect the aggregation of wild-type and A53T α-synuclein variants differently albeit similar membrane affinity
Artikel i vetenskaplig tidskrift, 2019

Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. α-Synuclein misfolding results in the accumulation of amyloid fibrils in Parkinson's disease. Missense protein mutations (e.g. A53T) have been linked to early onset disease. Although α-synuclein interacts with synaptic vesicles in the brain, it is not clear what role they play in the protein aggregation process. Here, we compare the effect of small unilamellar vesicles (lipid composition similar to synaptic vesicles) on wild-type (WT) and A53T α-synuclein aggregation. Using biophysical techniques, we reveal that binding affinity to the vesicles is similar for the two proteins, and both interact with the helix long axis parallel to the membrane surface. Still, the vesicles affect the aggregation of the variants differently: effects on secondary processes such as fragmentation dominate for WT, whereas for A53T, fibril elongation is mostly affected. We speculate that vesicle interactions with aggregate intermediate species, in addition to monomer binding, vary between WT and A53T, resulting in different consequences for amyloid formation. © The Author(s) 2019.

amyloid fibrils

membrane-bound α-synuclein

protein aggregation

small unilamellar vesicles

kinetic profiles

Författare

Sandra Rocha

Chalmers, Biologi och bioteknik, Kemisk biologi

Ranjeet Kumar

Chalmers, Biologi och bioteknik, Kemisk biologi

Istvan Horvath

Chalmers, Biologi och bioteknik, Kemisk biologi

Pernilla Wittung Stafshede

Chalmers, Biologi och bioteknik, Kemisk biologi

Protein engineering, design & selection : PEDS

17410126 (ISSN) 17410134 (eISSN)

Vol. 32 2 59-66

Ämneskategorier

Biokemi och molekylärbiologi

Biofysik

Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci)

DOI

10.1093/protein/gzz021

PubMed

31566224

Mer information

Senast uppdaterat

2021-02-23